China & Japan will be covered more or less with FDA approval.
CE Mark will cover Europe including the UK. Sales should come once the CE Mark and EU certification is received. Hence, sales should be in the second half of 2019, obviously assuming CE Mark approval by June.
Sales should be good since it’s around US $25,000 per dose. This is not insignificant. Even 100 doses translates to $US 2.5 million. 1000 doses equates to $US 25 million. Again not insignificant considering the size of the market in Europe alone.
Even the relatively small Aussie market will be good to launch in.
And this even before US, China and Japan.
Anyone Left?, page-61
-
- There are more pages in this discussion • 130 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $23.78M | |||
| Open | High | Low | Value | Volume |
| 0.6¢ | 0.7¢ | 0.6¢ | $116.5K | 16.65M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 12312335 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 3137908 | 9 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| OSL (ASX) Chart |